141 related articles for article (PubMed ID: 38556730)
1. Alpha-emitter therapy for pediatric relapsed metastatic pancreatic neuroendocrine tumor.
Wahba A; Delpassand ES; Nunez R; Esfandiari R; Venkatramani R
Pediatr Blood Cancer; 2024 Jun; 71(6):e30961. PubMed ID: 38556730
[No Abstract] [Full Text] [Related]
2. Large cardiac metastasis from pancreatic neuroendocrine tumor and response to peptide receptor radionuclide therapy with
Parghane RV; Basu S
J Nucl Cardiol; 2020 Feb; 27(1):340-341. PubMed ID: 30151794
[No Abstract] [Full Text] [Related]
3. Repeated peptide receptor radiotherapy in multiple recurrences of a metastasized neuroendocrine tumor.
Brogsitter C; Zöphel K; Folprecht G; Eisenhofer G; Kotzerke J
Nuklearmedizin; 2017 Jun; 56(3):N19-N21. PubMed ID: 28358166
[No Abstract] [Full Text] [Related]
4. Molecular Characterization and Treatment of Pancreatic Neuroendocrine Tumors.
De Jesus-Acosta AMC
Oncology (Williston Park); 2019 Dec; 33(12):. PubMed ID: 31914198
[No Abstract] [Full Text] [Related]
5. Emerging treatment modalities for advanced pancreatic neuroendocrine tumors.
Sindoni A; Famà F; Gioffre-Florio M; Baldari S
Hormones (Athens); 2016 Oct; 15(4):563-564. PubMed ID: 28222417
[No Abstract] [Full Text] [Related]
6. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Oberg K; Jelic S;
Ann Oncol; 2008 May; 19 Suppl 2():ii104-5. PubMed ID: 18456741
[No Abstract] [Full Text] [Related]
7. Therapy with radiolabeled somatostatin peptide analogs for metastatic neuroendocrine tumors.
Bushnell D
J Gastrointest Surg; 2006 Mar; 10(3):335-6. PubMed ID: 16622984
[No Abstract] [Full Text] [Related]
8. Aggressive gastro-entero-pancreatic neoplasms.
Coriat R
Ann Endocrinol (Paris); 2019 Jun; 80(3):185-186. PubMed ID: 31064660
[No Abstract] [Full Text] [Related]
9. Do morphologic characteristics play a role in nodal metastatic progression of well-differentiated pancreatic neuroendocrine tumors?
Ugras N; Hasdemir S; Yerci Ö; Taşar P; Dündar HZ; Macunluoğlu AC
Tumori; 2021 Feb; 107(1):80-85. PubMed ID: 32705937
[TBL] [Abstract][Full Text] [Related]
10. Nonfunctioning neuroendocrine pancreatic tumors: our experience and management.
Nomura N; Fujii T; Kanazumi N; Takeda S; Nomoto S; Kasuya H; Sugimoto H; Yamada S; Nakao A
J Hepatobiliary Pancreat Surg; 2009; 16(5):639-47. PubMed ID: 19365596
[TBL] [Abstract][Full Text] [Related]
11. Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor.
Stoeltzing O; Loss M; Huber E; Gross V; Eilles C; Mueller-Brand J; Schlitt HJ
Langenbecks Arch Surg; 2010 Feb; 395(2):185-92. PubMed ID: 19506898
[TBL] [Abstract][Full Text] [Related]
12. [Combined treatment of metastatic endocrine tumors of the gastrointestinal tract with octreotide and interferon-alpha].
Nold R; Frank M; Kajdan U; Trost U; Klose KJ; Arnold R
Z Gastroenterol; 1994 Apr; 32(4):193-7. PubMed ID: 7517086
[TBL] [Abstract][Full Text] [Related]
13. Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases.
Bertani E; Fazio N; Radice D; Zardini C; Grana C; Bodei L; Funicelli L; Ferrari C; Spada F; Partelli S; Falconi M
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):981-989. PubMed ID: 27613553
[TBL] [Abstract][Full Text] [Related]
14. Multimodal therapy with aggressive hepatectomy, everolimus, and octreotide for metastatic pancreatic neuroendocrine neoplasm enables 10-year survival.
Yumoto S; Nakagawa S; Hayashi H; Ogawa D; Shiraishi Y; Sato H; Matsumoto T; Imai K; Yamashita YI; Baba H
Clin J Gastroenterol; 2022 Dec; 15(6):1136-1144. PubMed ID: 36038805
[TBL] [Abstract][Full Text] [Related]
15. Management of pancreatic neuroendocrine tumors.
Dickson PV; Behrman SW
Surg Clin North Am; 2013 Jun; 93(3):675-91. PubMed ID: 23632152
[TBL] [Abstract][Full Text] [Related]
16. Metastatic pancreatic neuroendocrine tumor presenting as a pituitary space occupying lesion: a case report.
Gur C; Lalazar G; Salmon A; Dubiner V; Gross DJ
Pituitary; 2008; 11(3):293-7. PubMed ID: 17638085
[TBL] [Abstract][Full Text] [Related]
17. Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT).
Schiavo Lena M; Partelli S; Castelli P; Andreasi V; Smart CE; Pisa E; Bartolomei M; Bertani E; Zamboni G; Falconi M; Doglioni C
Endocr Pathol; 2020 Jun; 31(2):119-131. PubMed ID: 32361926
[TBL] [Abstract][Full Text] [Related]
18. SNM 2012 image of the year.
J Nucl Med; 2012 Oct; 53(10):23N. PubMed ID: 23028181
[No Abstract] [Full Text] [Related]
19. Peptide receptor radionuclide therapy implementation and results in a predominantly gastrointestinal neuroendocrine tumor population: A two-year experience in a nonuniversity setting.
Mejia A; Vivian E; Nwogu C; Shah J; Longoria R; Vo A; Shahin I; Verma J; Bageac A
Medicine (Baltimore); 2022 Mar; 101(9):e28970. PubMed ID: 35244064
[TBL] [Abstract][Full Text] [Related]
20. Ten-Year Survival After Peptide Receptor Radionuclide Therapy of a Metastatic Well-differentiated G3 Pancreatic Neuroendocrine Neoplasm.
Zhang J; Kulkarni HR; Singh A; Baum RP
Clin Nucl Med; 2018 Sep; 43(9):676-678. PubMed ID: 30080185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
